A hospital-based audit of gastro-duodenal ulcer prophylaxis for patients receiving non-steroidal anti-inflammatory drug and/or low dose aspirin therapy

2002 ◽  
Vol 97 (9) ◽  
pp. S243
Author(s):  
A SMITH
2013 ◽  
Vol 48 (5) ◽  
pp. 559-573 ◽  
Author(s):  
Tsuyoshi Fujita ◽  
Hiromu Kutsumi ◽  
Tsuyoshi Sanuki ◽  
Takanobu Hayakumo ◽  
Takeshi Azuma

2015 ◽  
Vol 163 (5) ◽  
pp. 347 ◽  
Author(s):  
Søren Friis ◽  
Anders H. Riis ◽  
Rune Erichsen ◽  
John A. Baron ◽  
Henrik T. Sørensen

2016 ◽  
Vol 27 (9) ◽  
pp. 1067-1079 ◽  
Author(s):  
Charlotte Skriver ◽  
Christian Dehlendorff ◽  
Michael Borre ◽  
Klaus Brasso ◽  
Henrik Toft Sørensen ◽  
...  

2009 ◽  
Vol 106 (2) ◽  
pp. 500-505 ◽  
Author(s):  
Lacy A. Holowatz ◽  
W. Larry Kenney

Full expression of reflex cutaneous vasodilation is dependent on cyclooxygenase- (COX) and nitric oxide synthase- (NOS) dependent mechanisms. Low-dose aspirin therapy is widely prescribed to inhibit COX-1 in platelets for atherothrombotic prevention. We hypothesized that chronic COX inhibition with daily low-dose aspirin therapy (81 mg) would attenuate reflex vasodilation in healthy human skin. Two microdialysis fibers were placed in forearm skin of seven middle-aged (57 ± 3 yr), normotensive, healthy humans with no preexisting cardiovascular disease, taking daily low-dose aspirin therapy (aspirin: 81 mg), and seven unmedicated, healthy, age-matched control (no aspirin, 55 ± 3 yr) subjects, with one site serving as a control (Ringer) and the other NOS inhibited (NOS inhibited: 10 mM NG-nitro-l-arginine methyl ester). Red cell flux was measured over each site by laser-Doppler flowmetry, as reflex vasodilation was induced by increasing core temperature (oral temperature) 1.0°C using a water-perfused suit. Cutaneous vascular conductance (CVC) was calculated (CVC = flux/mean arterial pressure) and normalized to maximal CVC (CVCmax; 28 mM sodium nitroprusside). CVCmax was not affected by either aspirin or NOS inhibition. The plateau in cutaneous vasodilation during heating (change in oral temperature = 1.0°C) was significantly attenuated in the aspirin group (aspirin: 25 ± 3% CVCmax vs. no aspirin: 50 ± 7% CVCmax, P < 0.001 between groups). NOS inhibition significantly attenuated %CVCmax in both groups (aspirin: 17 ± 2% CVCmax, no aspirin: 23 ± 3% CVCmax; P < 0.001 vs. control), but this attenuation was less in the no-aspirin treatment group ( P < 0.001). This is the first observation that chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation through both COX- and NOS-dependent mechanisms.


Sign in / Sign up

Export Citation Format

Share Document